Bioventus (NASDAQ:BVS) Reaches New 1-Year High on Better-Than-Expected Earnings

Key Points

• Bioventus stock hit a new 52-week high after reporting better-than-expected quarterly results — EPS of $0.15 versus consensus $0.09 on $132.09 million in revenue — and the company set FY2026 guidance of 0.750–0.790 EPS.
• Several analysts raised ratings and targets, leaving a MarketBeat consensus of Buy with a $14.00 price target after upgrades from firms including Craig Hallum, Cantor Fitzgerald and Barrington.
• Insider activity included Director Michelle Mcmurry‑Heath selling 12,000 shares, and ownership is concentrated with insiders at about 33% and institutional investors holding roughly 62.9% of the stock.

Bioventus Inc. (NASDAQ:BVS - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $10.86 and last traded at $10.81, with a volume of 248668 shares. The stock had previously closed at $10.68.

The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.06. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS.

Analysts Set New Price Targets

Several analysts have issued reports on BVS shares. Craig Hallum boosted their target price on Bioventus from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, March 6th. Cantor Fitzgerald raised shares of Bioventus to a "strong-buy" rating in a report on Wednesday, March 4th. CJS Securities assumed coverage on shares of Bioventus in a research report on Friday, March 27th. They set a "market outperform" rating and a $14.00 price target for the company. Finally, Barrington Research boosted their price target on shares of Bioventus from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Bioventus currently has a consensus rating of "Buy" and a consensus target price of $14.00.

Insider Transactions at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 33.00% of the company's stock.

Hedge Funds Weigh In On Bioventus

Hedge funds and other institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC raised its stake in Bioventus by 28.0% in the second quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company's stock worth $34,959,000 after buying an additional 1,155,192 shares in the last quarter. Hillsdale Investment Management Inc. grew its holdings in shares of Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company's stock valued at $6,128,000 after buying an additional 401,230 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in Bioventus during the fourth quarter valued at approximately $2,886,000. Kent Lake PR LLC bought a new position in Bioventus in the second quarter worth approximately $2,317,000. Finally, Kennedy Capital Management LLC raised its position in Bioventus by 219.6% in the third quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company's stock worth $3,088,000 after acquiring an additional 317,157 shares during the period. 62.94% of the stock is owned by institutional investors.

Bioventus Stock Up 2.1%

The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19. The firm has a market capitalization of $906.34 million, a P/E ratio of 32.75 and a beta of 0.72. The company's 50-day simple moving average is $9.23 and its two-hundred day simple moving average is $8.16.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.